Saturday, May 26, 2012 Last update: Yesterday, 6:04 PM
U.S. Technology Company News from the Inside
Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML)
Submitted by admin on 12/12/2011 @ 10:30 PM
Companies mentioned in this article:
Cell Therapeutics, Inc.
- Results Presented in Oral Session at the American Society of Hematology Annual Meeting